Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature

Internal and Emergency Medicine

Volumn 10, Issue 4, 2015, Pages 507-514

  Dentali, Francesco ^a   Di Minno, Matteo Nicola Dario ^b   Gianni, Monica ^c   Ambrosino, Pasquale ^d   Squizzato, Alessandro ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c Hospital of Tradate   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anticoagulants; Pulmonary embolism; Thromboembolism; Thrombosis; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOSIS;

EID: 84933179833     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-015-1249-x     Document Type: Article

References (22)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593. doi:10.1001/archinte.158.6.585
2. Middeldorp S, Prins MH, Hutten BA (2014) Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 8:CD001367. doi:10.1002/14651858.CD001367.pub3
3. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320–328. doi:10.1111/jth.12485
4. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. doi:10.1056/NEJMoa1113572
5. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE (2001) Extended out-of hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135:858–869. doi:10.7326/0003-4819-135-10-200111200-00006
6. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA (2002) Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 162:1465–1471. doi:10.1001/archinte.162.13.1465
7. Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. Lancet 379:1835–1846. doi:10.1016/S0140-6736(11)61904-1
8. Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, Monreal M, Investigators RIETE (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 117:1711–1716. doi:10.1161/CIRCULATIONAHA.107.726232
9. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6:e1000097. doi:10.1371/journal.pmed.1000097
10. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694. doi:10.1111/j.1538-7836.2005.01204.x
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12. doi:10.1016/0197-2456(95)00134-4
12. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101–105. doi:10.1136/bmj.323.7304.101
13. Schulman S, Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Mismetti P, Schellong S, Kreuzer J, Feuring M, Friedman J (2014) Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. Abstract in P5509, p 990. http://congress365.escardio.org/. Accessed 20 Oct 2014
14. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352. doi:10.1056/NEJMoa0906598
15. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, RE-COVERII Trial Investigators (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772. doi:10.1161/CIRCULATIONAHA.113.004450
16. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510. doi:10.1056/NEJMoa1007903
17. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. doi:10.1056/NEJMoa1113572
18. Investigators Hokusai-VTE, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415. doi:10.1056/NEJMoa1306638
19. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808. doi:10.1056/NEJMoa1302507
20. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134:774–782. doi:10.1016/j.thromres.2014.06.020
21. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124:1968–1975. doi:10.1182/blood-2014-04-571232
22. Vedovati MC, Becattini C, Germini F, Agnelli G (2014) Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. Int J Cardiol 177:601–603. doi:10.1016/j.ijcard.2014.08.136